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Abstract
Belfeed B is a feed additive with endo-1,4-beta-xylanase as the main enzymatic activity, that is
available in solid (MP) and liquid forms (ML). The production strain for Belfeed is a genetically modiﬁed
strain of Bacillus subtilis. Belfeed B does not give rise to safety concerns with regard to the genetic
modiﬁcation of the production strain. Neither the production strain nor its recombinant DNA was
detected in the ﬁnal product obtained from the production strain. The EFSA Panel on Additives and
Products or Substances used in Animal Feed (FEEDAP) concluded that the additive is safe for chickens
and turkeys for fattening, laying hens and weaned piglets at the dose of 10 IU/kg feed and this
conclusion was extended to chickens reared for laying, turkeys reared for breeding, breeding hens and
pigs for fattening and extrapolated to minor poultry species at the same dose. The production strain
belongs to a species considered to qualify for the qualiﬁed presumption of safety (QPS) approach to
safety assessment provided that the qualiﬁcations are met. The identity of the strain was
unambiguously established, the genetic modiﬁcation raised no concerns and the relevant qualiﬁcations
were met. Therefore, the FEEDAP Panel considered that the use of Belfeed B as a feed additive raises
no concerns for consumers. Data from toxicological studies supported this conclusion. The additive is
not considered to be toxic by inhalation or irritant for skin or eye, but it is considered a potential
respiratory sensitiser. The Panel could not conclude on its skin sensitisation potential. The use of
Belfeed B as a feed additive poses no risks to the environment. The Panel concluded that the additive
has the potential to be efﬁcacious at the dose of 10 IU/kg feed in the target species but owing to the
lack of sufﬁcient data the Panel cannot conclude on the efﬁcacy of the product in turkeys for fattening.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Belfeed B MP/ML as a feed additive for poultry species, piglets and pigs for fattening.
Belfeed B is a feed additive with endo-1,4-beta-xylanase as the declared enzymatic activity, that is
available in solid (MP) and liquid forms (ML). The production strain for Belfeed B is a genetically
modiﬁed strain of Bacillus subtilis. Belfeed B does not give rise to safety concerns with regard to the
genetic modiﬁcation of the production strain. Neither the production strain nor its recombinant DNA
was detected in the ﬁnal product obtained from the production strain.
Based on the tolerance trials evaluated the Panel concluded that the additive is safe for chickens
and turkeys for fattening, laying hens and weaned piglets at the dose of 10 IU/kg feed. The
Panel considered that the conclusions can be extended to chickens reared for laying, turkeys reared
for breeding, breeding hens and pigs for fattening. Also and based on the wide margin of safety
shown (100-fold) in major poultry species the Panel considers that the conclusions can be extrapolated
to minor poultry species at the same dose.
The production strain belongs to a species considered to qualify for the qualiﬁed presumption of
safety (QPS) approach to safety assessment provided that the qualiﬁcations are met. The identity of
the strain was unambiguously established, the genetic modiﬁcation raised no concerns and the
relevant qualiﬁcations were met. Therefore, the FEEDAP Panel considered that the use of Belfeed B as
a feed additive raises no concerns for consumers. Data from toxicological studies supported this
conclusion.
The additive is not considered to be toxic by inhalation or irritant for skin or eye, but the
Panel could not conclude on its skin sensitisation potential. Owing to the proteinaceous nature of the
active substance, the additive is considered a potential respiratory sensitiser.
The use of Belfeed B as a feed additive poses no risks to the environment.
Based on the results obtained in the efﬁcacy studies, the Panel concluded that the additive has the
potential to be efﬁcacious at the dose of 10 IU/kg feed in chickens for fattening, laying hens, weaned
piglets and pigs for fattening. The Panel considers that this conclusion can be extended to chickens
reared for laying and to breeding hens and can also be extrapolated to minor poultry species for
fattening and or laying/breeding. Owing to the lack of sufﬁcient data, the Panel cannot conclude on
the efﬁcacy of the product in turkeys for fattening.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7. Article 13(3) of that Regulation lays down that if the holder of
an authorisation proposes changing the terms of the authorisation by submitting an application to the
Commission, accompanied by the relevant data supporting the request for the change, the Authority
shall transmit its opinion on the proposal to the Commission and the Member States. Article 10(2) of
that Regulation also speciﬁes that for existing products within the meaning of Article 10(1), an
application shall be submitted in accordance with Article 7, at the latest 1 year before the expiry date
of the authorisation given pursuant to Directive 70/524/EEC for additives with a limited authorisation
period, and within a maximum of 7 years after the entry into force of this Regulation for additives
authorised without a time limit or pursuant to Directive 82/471/EEC.
The European Commission received a request from the company Beldem, a division of Puratos NV2
for authorisation/re-evaluation of the product Belfeed B MP/ML, endo-1,4-beta-xylanase, when used as
a feed additive for chickens for fattening, chickens reared for laying, laying hens, turkeys for fattening,
turkeys for breeding purposes, turkeys reared for breeding, ducks, piglets (weaned), pigs for fattening
and minor poultry species for fattening and laying (category: zootechnical additive; functional group:
digestibility enhancers).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application
to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of
a feed additive or new use of a feed additive), Article 13(3) (modiﬁcation of the authorisation of a
feed additive) and under Article 10(2) (re-evaluation of an authorised feed additive). EFSA received
directly from the applicant the technical dossier in support of this application. The particulars and
documents in support of the application were considered valid by EFSA as of 3 August 2011.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Belfeed B ML/MP (endo-1,4-beta-xylanase), when used under the proposed conditions of use
(see Section 3.1.5).
1.2. Additional information
The additive is a preparation of endo-1,4-beta xylanase produced by a genetically modiﬁed strain of
Bacillus subtilis (LMG-S 15136). The additive, is authorised in the European Union, in the form of
Belfeed B1100 MP/ML, as feed additive for chickens for fattening,3 piglets,4 ducks,5 pigs and turkeys
for fattening6 and laying hens.7 The currently authorised formulations, solid and liquid, have an
enzyme activity of 100 IU8/g or mL.
The Scientiﬁc Committee on Animal Nutrition issued an opinion on the safety of the solid form of
the additive for chickens for fattening and piglets (European Commission, 2002a) and for pigs for
fattening (European Commission, 2002b), another one on the safety of the liquid form for chickens for
fattening (European Commission, 2002c), and one on the safety and on the safety of the solid and
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Beldem, a division of Puratos NV, Rue Bourrie 12, 5300 Andenne, Belgium.
3 Commission Regulation (EC) No 1259/2004 of 8 July 2004 concerning the permanent authorisation of certain additives already
authorised in feedingstuffs. OJ L 239, 9.7.2004, p. 8.
4 Commission Regulation (EC) No 1206/2005 of 27 July 2005 concerning the permanent authorisation of certain additives in
feedingstuffs. OJ L 197, 28.7.2005, p. 12.
5 Commission Regulation (EC) No 242/2007 of 6 March 2007 concerning the authorisation of endo-1,4-beta-xylanase EC 3.2.1.8
(Belfeed B1100MP and Belfeed B1100ML) as a feed additive. OJ L 73, 13.3.2007, p. 1.
6 Commission Regulation (EC) No 516/2007 of May 2007 concerning the permanent authorisation of an additive in feedingstuffs.
OJ L 122, 11.5.2007, p. 22.
7 Commission Regulation (EC) No 322/2009 of 20 April 2009 concerning the permanent authorisations of certain additives in
feedingstuffs. OJ L 101, 21.4.2009, p. 9.
8 One International Unit (IU) is deﬁned as the amount of enzyme which liberates 1 lmol of reducing sugars (xylose equivalents)
from birchwood xylan per minute at pH 4.5 and 30°C.
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liquid forms for turkeys for fattening (European Commission, 2002d). EFSA issued an opinion on the
safety of the product for laying hens (EFSA, 2004) and on the safety and efﬁcacy for ducks (EFSA,
2006).
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier9 in support of the authorisation request for the use of product substance as a feed additive. The
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003,
Regulation (EC) No 429/2008 and the applicable EFSA guidance documents.
EFSA has veriﬁed the EURL report as it relates to the methods used for the control of the active
substance in animal feed. The Executive Summary of the EURL report can be found in Annex A.10
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Belfeed B is in
line with the principles laid down in Regulation (EC) No 429/200811 and the relevant guidance
documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012a), Technical guidance:
tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Technical Guidance for
assessing the safety of feed additives for the environment (EFSA, 2008a,b), Guidance for establishing the
safety of additives for the consumer (EFSA FEEDAP Panel, 2012b), Guidance on studies concerning the
safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012c), Guidance on the assessment
of the toxigenic potential of Bacillus species used in animal nutrition (EFSA FEEDAP Panel, 2014),
Technical Guidance: Extrapolation of data from major species to minor species regarding the assessment
of additives for use in animal nutrition (EFSA, 2008b), Guidance on the risk assessment of genetically
modiﬁed microorganisms and their products intended for food and feed use (EFSA GMO Panel, 2011).
3. Assessment
The additive Belfeed B is intended for use in chickens for fattening, chickens reared for laying,
laying hens, turkeys for fattening, turkeys for breeding purposes, turkeys reared for breeding, ducks,
piglets (weaned), pigs for fattening and minor poultry species for fattening and laying as a
zootechnical additive (digestibility enhancers). The current assessment deals with the re-evaluation of
the additive, however, a change in the ﬁnal formulations of the additive has also been proposed. The
applicant is requesting also to extend the authorisation to poultry species/categories other than those
in which is already authorised.
3.1. Characterisation12
3.1.1. Characterisation of the active substance
The main activity contained in the additive is endo-1,4-beta-xylanase (EC 3.2.1.8; xylanase). This
xylanase is produced by a genetically modiﬁed strain of Bacillus subtilis. Other side enzyme activities
may be present in the ﬁnal additive, beta-glucanase and alpha-amylase.
3.1.1.1. Information relating to the genetically modiﬁed microorganism
The production strain is B. subtilis, deposited at the LMG culture collection (Belgian Co-ordinated
Collections of Microorganisms, University of Ghent) with deposition number LMG S-15136. The strain
was identiﬁed by phylogenetic analysis of the gene sequence of the 16S ribosomal RNA,13 cell
morphology, biochemical traits and fatty acid proﬁle.14
9 FEED dossier reference: FAD-2010-0285.
10 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/default/ﬁles/ﬁnrep-fad-2010-0285-belfeed.pdf
11 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
12 This section has been amended following the conﬁdentiality claims made by the applicant.
13 Technical dossier/Supplementary information September 2014.
14 Technical dossier/Section II/Annex II.09.
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The parental strain is Bacillus subtilis Marburg 168. B. subtilis has been recommended for qualiﬁed
presumption of safety (QPS) with the qualiﬁcation that the absence of toxigenic potential has to be
veriﬁed for the strain used (EFSA BIOHAZ Panel, 2013). The genome of strain B. subtilis Marburg 168
has been fully sequenced and is publicly available. Bioinformatic analyses searching for homology with
known toxins and surfactins, PCR detection of non-ribosomal peptide synthase genes to identify
surfactin-positive strains, and tests for haemolysis and cytotoxicity tests with Vero cells yielded
negative results for the parental strain B. subtilis Marburg 168, indicating that this strain is not
toxigenic.15 The technical dossier contains detailed and sufﬁcient information on the recipient
microorganism, including aspects on the safety of the strain lineage, the origin and function of the
different genetic elements introduced in the production strain, the genetic modiﬁcation process and
the genetic and phenotypic traits introduced.16–18
3.1.2. Manufacturing process
Belfeed B is produced by submerged, pure culture fermentation of the production strain. The
enzyme is secreted into the culture broth. The substrate (sugar, proteins, salt) is mixed, sterilised and
fermented by Bacillus subtilis in a closed system. The fermentation product, containing xylanase (and
side activities beta-glucanase and alpha-amylase) is separated from the biomass by micro-ﬁltration.
The enzymatic ﬁltrate is concentrated. As a result of a modiﬁcation of the manufacturing, the resulting
product has a higher enzyme activity than in the past which permits to prepare formulations with
higher enzyme activity. The enzyme concentrate is ﬁltered and spray-dried on a carrier (food grade
wheat ﬂour) or mixed with glycerol to produce the two preparations of the additive, solid and liquid,
respectively. No antimicrobials are used in the manufacturing of the product.
3.1.3. Characterisation of the additive
The additive is available in solid and liquid forms.
The solid formulation, Belfeed B MP, ensures a minimum of 400 IU8/g. The study of the batch-
to-batch variation in six batches showed a mean value of 420 IU/g ranging from 412 to 434 IU/g
(coefﬁcient of variation (CV) 1.9%).19 This formulation contains the liquid enzyme concentrate
(including the elution acetate buffer) spray-dried on food grade wheat ﬂour (minimum of 90%). The
particle size of three batches of the additive was measured by laser diffraction and showed a particle
size of 107 lm (median value) with less than 25% (v/v) of the particles with a diameter of 50 lm and
less than 4% (v/v) of the particles with a diameter of 10 lm.20 The dusting potential was measured in
one batch using the Stauber–Heubach method (triplicate), the dust amounted 0.187 g/m3.21 The bulk
density is 660 kg/m3.
The liquid formulation, Belfeed B ML, also ensures a minimum of 400 IU/g. The study of the batch-
to-batch variation in ﬁve batches showed a mean value of 428 IU/g ranging from 416 to 441 IU/g
(CV 2.5%).22 This formulation contains the liquid enzyme concentrate (including the elution acetate
buffer) and glycerol (maximum 30%). It has a density similar to 1,050–1,100 kg/m3,23 a viscosity of
2.65–2.70 centipoises (at 20°C) and a pH of 4.19–4.22.24
Three batches of the enzyme concentrate were analysed for chemical and microbial contamination.25
Microbial contamination included the study of Salmonella spp. (absent/25 g), Bacillus cereus
(< 100 colony forming units (CFU)/g), coagulase-positive Staphylococcus (< 10 CFU/g), coliforms (30°C,
< 10 CFU/g), b-glucuronidase positive E. coli (< 10 CFU/g), yeasts (100 CFU/g), ﬁlamentous fungi
(100 CFU/g), enterococci (< 100 CFU/g), Clostridium perfringens (10 CFU/g) and sulphite-reducing
anaerobic bacteria 37°C (< 10 CFU/g). The chemical contamination included the study of arsenic
(< 0.05 mg/kg), cadmium (< 0.01 mg/kg), mercury (< 0.01 mg/kg), lead (0.02 mg/kg) and mycotoxin
deoxynivalenol (< 50 lg/kg), aﬂatoxins B1, B2, G1, G2 (< 1 lg/kg), T2 toxin (< 20 lg/kg), HT2 toxin
15 Technical dossier/Section III/Annex III.13.
16 Technical dossier/Supplementary information June 2013 and November 2014.
17 Technical dossier/Conﬁdential parts/Annex III.13 conf.
18 Technical dossier/Supplementary information March 2014, September 2014 and November 2014.
19 Technical dossier/Supplementary information June 2013/Annex Q05-1.
20 Technical dossier/Supplementary information June 2013/Annex Q07-1.
21 Technical dossier/Supplementary information March 2014/Annex Q(ii)_1 and 2.
22 Technical dossier/Supplementary information June 2013/Annex Q-05-1.
23 Technical dossier/Section II.
24 Technical dossier/Supplementary information March 2014/Annex Q(iii)_1 to 3.
25 Technical dossier/Supplementary information June 2013/Annex Q06-1.
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(< 20 lg/kg), fumonisine B1 and B2 (< 50 lg/kg), nivalenol (< 200 lg/kg), a and b-zearalenol
(< 20 lg/kg), ochratoxin A (< 0.50 g/kg) and cytochalasin E (< 2 lg/kg). Antimicrobial activity was
found to be absent when analysed following the method speciﬁed by the Joint FAO/WHO Expert
Committee on Food Additives (FAO JECFA, 2006).26 The production strain was not detected in a test
volume of 1 mL of three batches of the liquid concentrate before formulation, each sample tested in
triplicate.27 No recombinant DNA from the production strain B. subtilis was detected in four batches of
concentrate before formulation, each tested in triplicate by PCR.27
3.1.4. Shelf life and stability
3.1.4.1. Shelf life
Three batches of the solid and the liquid formulations were stored in closed packages at 25°C for
13 or 12 months, respectively, or at 40°C for 16 or 12 weeks, respectively.28 The samples of the liquid
formulation were also kept at 4°C for 12 months. The initial enzyme activity ranged 416–434 IU/g for
the solid and 416–441 IU/g for the liquid. After 12 months of storage at 25°C, the recoveries of the
two formulations showed no modiﬁcations of the initial enzyme activity. After 16 weeks at 40°C, the
solid formulation showed recoveries of 94%, the recoveries of the liquid formulation were below 60%
after 3 weeks. After 12 months, no modiﬁcations on the enzyme activity were found in the liquid
formulation kept at 4°C.
3.1.4.2. Stability and homogeneity of the additive in premixtures
Three batches of the solid and liquid formulations were added to three different complete
premixtures: one for chickens for fattening, one for laying hens and one for pigs (containing choline
chloride).29 Supplementation was at 1,000 IU/kg premixture for the pig and chickens and at 500 IU/kg
premixture for the layers. The samples were stored in sealed plastic bags at room temperature (not
exceeding 25°C) for 24 weeks. Recoveries were similar to 100% regardless of the premixture and
additive form considered.
Six subsamples of premixtures supplemented with the solid or with the liquid formulations were
analysed to check the capacity of the additive to homogeneously distribute. The average enzyme
activity for the solid form was 1,029 IU/kg premixture and for the liquid it was 1,027 IU/kg. The CV of
the samples analysed for the solid was 3% and for the liquid it was of 4%.
3.1.4.3. Stability and homogeneity of the additive in feed
Three batches of the solid formulation were added to two mash diets, one for chickens for
fattening, and one for pigs, based on cereals and soya bean meal.30 Supplementation was at the
recommended level and the recoveries were measured after 12 weeks. The samples were kept in
sealed plastic bags at room temperature (not exceeding 25°C). Recoveries were higher than 90%. A
further batch was added to a mash feed for piglets at three dosages (10, 25 and 50 IU/kg feed) and
kept at room temperature for 24 weeks. No losses on the enzyme activity were recorded.23
Two batches of a diluted version of the solid formulation (currently authorised) were added to mash
feed for chickens for fattening (based on maize and soya bean meal) and then pelleted at 65°C.31
Samples were stored in sealed plastic bags at room temperature (not exceeding 25°C). Measurements
of xylanase were performed after pelleting and after 12 weeks. Recoveries were higher than 96% in all
cases. The effect of the heat process on the enzyme activity was studied in two more batches of a
diluted version of the solid formulation.23 One batch was added to feed at 2,000 IU/kg and subject to
pelleting at 65, 75 or 85°C (or not pelleted). Recoveries were 86%, 67% and 89% compared to the
non-pelleted diet. Another batch was added to feed at 10 IU/kg and pelleted at 75°C, and the enzyme
activity was followed for 24 weeks; no details were available on the storage conditions. The losses after
pelleting were similar to 25% and thereafter the enzyme activity remained stable for the 24 weeks.
Three batches of the liquid formulation were added to a pelleted diet for chickens for fattening
based on maize and soya bean meal.32 Supplementation was at the recommended level and the
26 Technical dossier/Supplementary information September 2014/Annex 1.
27 Technical dossier/Supplementary information June 2013.
28 Technical dossier/Supplementary information June 2013/Annex Q08-1 and Supplementary information March 2014.
29 Technical dossier/Supplementary information June 2013/Annex Q11-1 and Supplementary information March 2014.
30 Technical dossier/Supplementary information June 2013/Annex Q13-1 and Supplementary information March 2014.
31 Technical dossier/Supplementary information June 2013/Annex Q13-2 and Supplementary information March 2014.
32 Technical dossier/Supplementary information June 2013/Annex Q13-3 and Supplementary information March 2014.
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recoveries were measured after 12 weeks. The samples were stored in sealed plastic bags at room
temperature (not exceeding 25°C). Recoveries after 12 weeks were higher than 92%. A further batch
was added to a mash feed based on cereals and cereal by-products at 10 IU/kg feed and stored at
room temperature for 16 weeks. No losses on the enzyme activity were found.23
The capacity of the solid and liquid formulations to homogeneously distribute was studied when
added to a feed for pigs at the recommended dose in mash and/or pelleted feed.33 Three batches of
each formulation were studied and 10 subsamples of the feeds were analysed. The CV of the enzyme
activity in feed supplemented with the solid formulation ranged from 4.1% to 7.9% for the mash feed
and from 4.6% to 8.7% in the pelleted feed and the CV for the pelleted feeds supplemented with the
liquid formulation ranged from 4.4% to 4.8%.
3.1.5. Conditions of use
Belfeed B MP/ML is intended to be used at a dose of 10 IU/kg feed in complete feed for chickens
for fattening or reared for laying, turkeys, laying hens, ducks, other minor poultry species for fattening
and laying, weaned piglets and pigs for fattening. The liquid formulation is to be added to the feed
mainly after pelleting.
3.2. Safety
3.2.1. Safety of the genetic modiﬁcation and of the strain34
The parental organism, B. subtilis Marburg 168, is considered to be safe. The introduced trait is
well known and does not raise any safety concern. Analyses revealed that neither the production strain
nor the recombinant DNA was present in the ﬁnal product. The ﬁnal product does not raise any safety
concern with regard to the genetic modiﬁcation of the production strain.
3.2.2. Safety for the target species
The test materials used in the tolerance studies were not the products described in the
characterisation section, but the currently authorised formulation of the additive (four times diluted).
The Panel considers that these test materials are adequate and will be referred in the studies below as
Belfeed B xylanase (the form is indicated).
3.2.2.1. Safety for chickens for fattening
A total of nine hundred 1-day-old male chicks (Ross 308) were distributed in 30 pens of 30 birds
each and allocated to three dietary treatments (10 replicates per treatment).35 The basal diets (starter,
grower and ﬁnisher) based on wheat, maize and soya bean meal were supplemented with Belfeed B
xylanase (solid) at 0, 10 (19) or 1,000 (1009) IU/kg feed. The enzyme activities were conﬁrmed by
analysis. The feed was offered to the birds ad libitum in mash form for 39 days (starter, 1–13 days;
grower, 13–26 days; ﬁnisher, 26–39 days). Mortality and health status were monitored throughout the
study. Feed consumption and body weight of the birds were measured when the diets were changed
and at the end of the study. An analysis of variance (ANOVA) was done on the data, pen basis, means
were compared using the Dunnett’s test and differences were considered signiﬁcant at a level of at
least p < 0.05.
Mortality was low and amounted to 1.3% in all treatments. Mean daily feed intake of the birds was
104, 104 and 106 g for 0, 19 and 1009, respectively, and was not affected by the treatments. Final
body weight was 2.51, 2.61 and 2.67 kg for 0, 19 and 1009, respectively, and the corresponding
ﬁgures for the feed to gain ratio were 1.64, 1.59 and 1.57. The supplementation of the xylanase at
either dose resulted in a statistically signiﬁcant higher body weight and better feed to gain ratio as
compared to the control diet. Feeding the birds with Belfeed B xylanase up to 100-fold the
recommended dose did not have any negative effects on the performance parameters. Therefore, the
FEEDAP Panel concludes that the product is safe for chickens for fattening at the recommended dose.
33 Technical dossier/Supplementary information January 2016/Annex 1.
34 This section has been amended following the conﬁdentiality claims made by the applicant.
35 Technical dossier/Supplementary information June 2013 Annex Q16-1 and Q16-2 and supplementary information March 2014/
Annex Q(vi)_1/Supplementary information June 2016b.
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3.2.2.2. Safety for turkeys for fattening
A total of four hundred and thirty-two 1-day-old male turkeys (Hybrid Grade makers) were
distributed in 24 cages of 18 birds each (cages of 2.6 m2) and allocated to three dietary treatments
(eight replicates (cages) per treatment).36 The basal diets (starter and grower) based on wheat, corn
and soybean meal were supplemented with Belfeed B xylanase (solid) at 0, 10 (19) or 1,000
(1009) IU/kg feed. This diet contained monensin. The enzyme activities were conﬁrmed by analysis.
Feed was offered to the birds ad libitum for 42 days. The feed was offered in crumble form during the
starter phase (0–21 days) and granulated during the grower phase (21–42 days). Mortality and health
status were monitored throughout the study. Feed consumption and body weight of the birds were
measured on days 21 and 42 of the study by cage. Feed to gain ratio was calculated. An ANOVA was
done on the performance data, cage basis and the initial body weight was considered as covariate in
the model. The differences were considered signiﬁcant at a level of at least p < 0.05.
No animals died; only two were culled (one from 0 and another one from 1009). Mean daily feed
intake of the birds was 99, 100 and 97 g for 0, 19 and 1009, respectively, and was not affected by
the treatments. Final body weight was 2.94, 2.96 and 2.95 kg for 0, 19 and 1009, respectively, and
the corresponding ﬁgures for the feed to gain ratio were 1.44, 1.46 and 1.41. The supplementation of
Belfeed B xylanase at 1009 dose resulted in a statistically signiﬁcant better feed to gain ratio as
compared to the control diet. Feeding the birds with the xylanase up to 100-fold the recommended
dose did not have any negative effects on the performance parameters. Therefore, the FEEDAP
Panel concludes that the product is safe for turkeys for fattening at the recommended dose.
3.2.2.3. Safety for laying hens
A total of two hundred and eighty-eight 16-week-old hens (Hy-Line Brown) were distributed in 36
enriched cages of eight hens each. From 16 to 17 weeks of age, the animals were fed a pre-laying
commercial diet without enzyme additive. At 23 weeks, they were allocated to three dietary treatments
(12 replicates (cages) per treatment).37 A basal diet based on wheat, rye and soya bean meal was
supplemented with Belfeed B xylanase (solid) at 0, 10 (19) or 1,000 (1009) IU/kg feed. The enzyme
activities were conﬁrmed by analysis. The feed was offered in mash form and ad libitum for 56 days.
Mortality and general health were monitored throughout the study. Body weight per replicate (cage)
was recorded at the beginning and at the end of the trial. Feed consumption was recorded at day 28
and day 56 per cage. Egg production per cage was recorded and weighed every second day. Feed to
egg mass ratio was calculated. The number of broken, shell-less and dirty eggs was recorded. An
ANOVA was performed on the data obtained, cage basis, and differences were considered signiﬁcant
at a level of at least p < 0.05.
No mortality was reported. Mean daily feed intake of the hens was 114, 110, 111 g for 0, 19 and
1009, respectively, and was signiﬁcantly lower in the diets supplemented with xylanase (19)
compared to the control. Laying rate was 95.8%, 95.4% and 94.7% for 0, 19 and 1009, respectively,
and the corresponding ﬁgures for egg weight were 58.8, 59.1 and 58.1 g and the feed to egg mass
ratio were 2.03, 1.95 and 2.02. No statistically signiﬁcant differences were observed for these
parameters in the 1009 group compared to the control. The addition of xylanase at the recommended
dose (19) improved signiﬁcantly the feed to egg mass ratio compared to the other treatments.
Feeding the birds with xylanase up to 100-fold the recommended dose did not have any negative
effects on the performance parameters. Therefore, the FEEDAP Panel concludes that the product is
safe for laying hens at the recommended dose.
3.2.2.4. Safety for minor poultry species
The applicant submitted a trial with Muscovy ducks which had been previously evaluated by the
FEEDAP Panel (EFSA, 2006). In that trial, three treatments were considered – a non-supplemented diet
and two diets supplemented with the Belfeed B xylanase at 10 (19) or 100 (109) IU/kg feed.
Mortality and health status were monitored. Performance of the birds was also measured. The results
showed no adverse effects of the additive on the performance of the birds at the highest dose, but no
data were available on the haematological/biochemical parameters in blood.
36 Technical dossier/Supplementary information June 2013 Annex Q16-3 and Supplementary information March 2014/Annex Q(vi)_2.
37 Technical dossier/Supplementary information June 2013 Annex Q16-4 and Q16-5 and Supplementary information March 2014/
Annex Q(vi)_3 and Annex Q(vii)_1.
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Based on the wide margin of safety shown, the conclusions from the major poultry species can be
extrapolated to minor poultry species. The results obtained in the study in ducks are considered as
supportive evidence on the safety of the product in minor poultry species for fattening.
3.2.2.5. Safety for piglets
A total of 144 male and female piglets (Pietrain 9 (Landrace 9 Large white), 21 days old) were
distributed randomly in a total of 24 ﬂoor pens in groups of six piglets and allocated to three dietary
treatments (eight replicates per treatment).38 Upon arrival, the animals were administered an
intramuscular dose of tulathromycin and from day 21 to day 26 of life, piglets were fed a post-weaning
adaptation diet (medicated feed). The piglets received the experimental diets from day 26 of life
(mean body weight 6.7 kg). Two basal diets (pre-starter and starter) based on wheat, milk whey, rye,
barley and soya bean meal were supplemented with Belfeed B xylanase at 0, 10 (19) or 1,000 IU/kg
feed (1009). The enzyme activity was conﬁrmed by analysis. The feed was offered in pelleted form
and ad libitum for 42 days. Mortality and health status were monitored throughout the study. Body
weight and feed intake were measured on days 14, 29 and 42 of study (body weight at the beginning
as well). An ANOVA was performed on the data obtained. The model included the effect of the diet
and the block (weight and location), and differences were considered signiﬁcant at a level of at least
p < 0.05.
Four pigs of the non-supplemented diet died, three in treatment 19 and two on treatment 1009.
The mean daily feed intake was 569, 570 and 555 g for 0, 19 and 1009, respectively, and the
corresponding ﬁgures for ﬁnal body weight were 25.3, 25.5, 25.7 kg and for feed to gain were 1.30,
1.28 and 1.23. The 1009 treatment showed a better feed to gain ratio compared to the other groups.
Feeding the piglets with xylanase up to 100-fold the recommended dose did not have any negative
effects on the performance parameters. Therefore, the FEEDAP Panel concludes that the additive is
safe for weaned piglets at the recommended dose.
3.2.2.6. Safety for pigs for fattening
No speciﬁc study was provided to demonstrate the tolerance of pigs for fattening. The FEEDAP
Panel considers that the conclusions reached with regard to piglets can be extended to pigs for
fattening.
3.2.2.7. Conclusions on safety for the target species
The tolerance trials provided in chickens and turkeys for fattening, laying hens and weaned piglets
showed that the animals can tolerate up to 100-fold the recommended dose of 10 IU xylanase/kg
feed. Therefore, the FEEDAP Panel concludes that the additive is safe for these target species/
categories at that dose.
The Panel considers that the conclusions reached for the chickens and turkeys for fattening can be
extended to chickens reared for laying and turkeys reared for breeding, and the conclusions for laying
hens can be extended to breeding hens at the same dose. Similarly, the conclusions for weaned piglets
can be extended to pigs for fattening at the same dose.
Based on the wide margin of safety shown, the conclusions on the safety for the major poultry
species can be extrapolated to ducks and other minor poultry species for fattening and for laying at
the same dose.
3.2.3. Safety for the consumer
The toxicological studies are not required if the fermentation product is produced by a genetically
modiﬁed microorganism that is considered by EFSA to qualify for the QPS approach to safety
assessment and the genetic modiﬁcation raises no concerns. The enzyme is produced by a genetically
modiﬁed strain of B. subtilis; this species is considered to qualify for the QPS approach to safety
assessment provided that the qualiﬁcations are met. The identity of the strain was unambiguously
established, the genetic modiﬁcation raised no concerns and the relevant qualiﬁcations were met.
Therefore, the FEEDAP Panel concludes that the use of Belfeed B as a feed additive raises no concerns
for consumers.
The applicant provided various toxicity studies to support the safety of the product: two acute
toxicity studies, four genotoxicity studies and one sub-chronic oral toxicity study. The two acute oral
38 Technical dossier/Supplementary information June 2013 Annex Q16-6 and Supplementary information March 2014/Annex Q(vi)_2.
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toxicity studies,39,40 did not show any sign of acute toxicity. The two bacterial reverse mutation
assays,41,42 performed in Salmonella Typhimurium (strains TA 1535, TA 1537, TA 98 and TA 100) and
in one case in Escherichia coli CM8991 (WP2uvrA/pKM101) showed no evidence of mutagenic activity.
No evidence of clastogenic activity was found in an in vitro chromosomal aberration test in human
lymphocytes43 and no induction of micronuclei was reported in the in vivo mammalian micronucleus
test.44 Moreover, no treatment-related adverse effects were reported in the sub-chronic oral toxicity
test performed in rats.45 Although in most of the provided studies, with the exception of one of the
genotoxicity studies,44 the test item was not derived from the manufacturing process that is currently
used to obtain the xylanase, the Panel considers these data supportive of the safety of the product.
3.2.4. Safety for the user
The studies under this section were performed with the fermentation product that was used in the
past to obtain the additive, below referred as test item.46 Considering the characteristics of the
products obtained after the fermentation, the Panel considers that the results obtained in the below
studies are relevant to the fermentation product that is currently used to formulate the additive.
3.2.4.1. Effects on the respiratory system
An acute inhalation toxicity study was performed on Sprague-Dawley rats exposed for 4 h to an
aerosol containing a mean concentration of 6.08 mg test item/L, according to OECD Guideline 403.47
No treatment-related signs were reported during the observation period or at the end of the study.
Owing to the proteinaceous nature of the active substance, the additive is considered as a potential
respiratory sensitiser. The solid form has less than 4% of particles with a diameter of 10 lm and
therefore there is a potential exposure by inhalation; however, the dusting potential is low.
3.2.4.2. Effects on the skin and eyes
An acute dermal irritation study was performed on three New Zealand White rabbits, according to
OECD Guideline 404.48 The test item was tested by a single exposure to 0.5 mL of the material for
4 h. Responses were recorded after 1, 24, 48 and 72 h and no dermal reaction was detected.
The potential of the test item to induce eye irritation was assessed in three New Zealand White
rabbits according to the OECD Guideline 405.49 Ocular reactions were assessed at 1, 24, 48 and 72 h
after treatment. Very slight conjunctiva redness was observed after 1 and 24 h. The eyes were overtly
normal at the 48-h examination. Therefore, under the conditions of this test, the test item was
classiﬁed as non-irritant to the eye.
No data were provided on dermal sensitisation potential.
3.2.4.3. Conclusions on safety for the user
The studies under this section were performed with the fermentation product that was used in the
past to formulate the product. The results are considered to be relevant to the fermentation product
that is currently used to formulate the additive. The fermentation product did not prove to be toxic by
inhalation or irritant for skin or eye and the ingredients used to formulate the additive are not likely to
contribute to the irritant properties. Owing to the lack of data, the Panel cannot conclude on the skin
sensitisation potential of the additive. Because of the proteinaceous nature of the active substance, the
additive is considered a potential respiratory sensitiser.
3.2.5. Safety for the environment
Neither the production strain nor its recombinant DNA was detected in the ﬁnal product. The ﬁnal
product does not raise any environmental safety concern associated with the genetic modiﬁcation of
39 Technical dossier/Section III/Annex III.11.
40 Technical dossier/Section III/Annex III.7.
41 Technical dossier/Section III/Annex III.9.
42 Technical dossier/Section III/Annex III.8.
43 Technical dossier/Section III/Annex III.10.
44 Technical dossier/Supplementary information June 2013/Annex Q17.1.
45 Technical dossier/Section III/Annex III.12.
46 Technical dossier/Supplementary information March 2014.
47 Technical dossier/Section III/Annex III.14.
48 Technical dossier/Section III/Annex III.15.
49 Technical dossier/Section III/Annex III.16.
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the production strain. The active substance of the additive is a protein, and as such will be degraded/
inactivated during passage through the digestive tract of animals or in the environment. Therefore, no
risks to the environment are expected and no further environmental risk assessment is required.
3.3. Efﬁcacy
The test materials used in the efﬁcacy studies were not the products described in the section on
characterisation, but the currently authorised formulations of the additive, diluted four times. The
Panel considers that these test materials are adequate and will be referred in the studies below as
Belfeed B xylanase. Indications on the formulation, solid or liquid are also provided.
3.3.1. Efﬁcacy for chickens for fattening
A total of 11 efﬁcacy trials (including the tolerance trial) were evaluated. Eight trials were not
considered further in the assessment due to different reasons: one trial due to the short duration and
the type of parameters measured (28 days, performance), two more due to the high mortality
(> 6%)50 and the other ﬁve trials51 could not be considered due to the fact that the raw data were not
available anymore and the statistical analysis of the data could not be redone according to the current
requirements. Therefore, the trials that were considered in the assessment were one short-term trial
and two long-term trials.
In the short-term trial,52 one hundred and forty-four 1-day-old male chickens (Cobb) were
distributed to cages in groups of six, according to the body weight, and the cages were allocated to
one of the four dietary treatments (representing six replicates per treatment). The study followed a
2 9 2 factorial design with two basal diets differing in the metabolisable energy (ME) content (gross
energy content 18.40 or 19.57 MJ/kg feed dry matter basis) and two supplemented levels of Belfeed B
xylanase in solid form (0 or 10.5 IU/kg feed, analysed doses 8.7 and 9.3 IU/kg feed for low energy
and high energy content, respectively). The basal diets were based on wheat and soya bean meal and
differed in the oil content. The animals were under study for 14 days and a balance took place for
3 days. Feed intake and body weight of the birds were measured during the study, and feed and
excreta samples were analysed in order to study the energy content. An ANOVA was performed with
the data in order to study the effect of the energy content and the effect of the enzyme and their
interaction. The results showed that the addition of the enzyme at 10.5 IU/kg feed resulted in a
signiﬁcantly higher ME content of the diets (apparent ME nitrogen-corrected control: 13.93 Belfeed B
xylanase: 14.19 MJ/kg dry matter feed) compared to control.
In the ﬁrst long term trial, a total of ﬁve hundred and forty 1-day-old male and female chickens
(Ross) were distributed (sex separated) to pens in groups of 30 birds and allocated to three dietary
treatments, whereas at the start of the growing period, the animals were split into two pens
(representing 12 replicates per treatment).53 The basal diet based on wheat and soya bean meal was
either not supplemented (control) or supplemented with Belfeed B xylanase in solid or liquid form at
10.5 IU/kg feed. The enzyme activities were conﬁrmed by analysis (10.4 and 10.3 IU/kg feed). Feed
was offered to the birds ad libitum for 42 days. Mortality and health status were monitored throughout
the study. Feed consumption and body weight of the birds was measured on days 14 and 42 of the
study. Feed to gain ratio was calculated. An ANOVA was done on the performance data, pen basis,
considering the effect of the treatment, the sex and their interaction and mean values were compared
using the Dunnett method.54 The differences were considered signiﬁcant at a level of at least
p < 0.05. The results are presented in Table 1, trial 1. The results showed a signiﬁcant effect of the
enzyme, in either form, on the body weight and feed to gain ratio of the chickens.
The second long-term trial is the tolerance trial in chickens for fattening that has been presented in
Section 3.2.2 and the results are shown in Table 1, trial 2. There was a signiﬁcant effect of the
additive on the ﬁnal body weight and on the feed to gain ratio.
50 Technical dossier/Section IV/Annex.IV.01.01, 01.04 and 01.06.
51 Technical dossier/Section IV/Annex IV.01.02, 01.03, 01.07, 01.08 and 01.09.
52 Technical dossier/Section IV/Annex IV.01.10.
53 Technical dossier/Section IV/Annex IV.01.05/Supplementary information June 2016/Annex.
54 Data on the daily feed intake were not evaluated using this methodology; means in the table were compared using LSMEANS.
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The addition of the enzyme to the feed resulted in an increased ME content in one trial and in a
higher body weight and better feed to gain ratio in two trials. Therefore, the FEEDAP Panel concludes
that Belfeed B xylanase is efﬁcacious at the dose of 10 IU/kg feed in chickens for fattening. This
conclusion can be extended to chickens reared for laying.
3.3.2. Efﬁcacy for turkeys
A total of six trials were evaluated, one55 was not further considered in the assessment due to the
lack of a control (i.e. the non-supplemented diet had a different composition compared to the diets
supplemented with the additive) and another was not further considered due to the high mortality/
culling registered during the study (> 10%).56
The details of the design of the other four studies are provided in Table 2 and the results in
Table 3. In all trials, 1-day-old birds were used, in trials 1 and 4, males were used and in trial 3,
females were used. In trial 2, males and females were used and were kept sex separated. In the four
studies the birds were treated either with a non-supplemented diet (control) or with a diet containing
Belfeed B xylanase at 10 IU/kg feed (conﬁrmed by analysis). Health and mortality were monitored
throughout the study, and body weight and feed intake were recorded. Feed to gain ratio was
calculated. The data were analysed with an ANOVA, pen basis.
Table 1: Effects of Belfeed B on the performance of chickens for fattening
Trial
Enzyme activity
(IU/kg)
Daily feed
intake (g)
Final body
weight (g)
Feed to
gain
Mortality and
culling (%)
1 0 75b 1,875b 1.73a 2.1
10.5 solid 78a 1,995a 1.69b 1.1
10.5 liquid 78a 2,006a 1.68b 2.1
2 0 104 2,515b 1.64a 1.3
10 104 2,608a 1.59b 1.3
1,000 106 2,671a 1.57b 1.3
a,b: Within a column and within a trial, values with a different superscript are signiﬁcantly different (p < 0.05).
Table 2: Trial design and dosages of the efﬁcacy trials performed in turkeys for fattening
Trial
Total no. animals
(animals/replicate)
replicates/treatment
Breed
Duration
Sex
Diet composition
Enzyme activity
(IU/kg feed)
Intended Analysed
1(a) 486
(27)
6
BUT 9
16 w
♂
Wheat, soya bean meal 0
10.5 solid
10.5 liquid
0
8.7–9.4
8.8–9.4
2(b) 300♂/372♀
(25/31)
8
BUT 9
16/12 w
♂/♀
Wheat, soya bean meal 0
10.5 solid
10.5 liquid
0
8.5–9.5
7.9–9.1
3(c) 320
(40)
4
BUT 9
15 w
♀
Wheat, triticale, soya
bean meal
0
10.5 solid
0
8.2–10.5
4(d) 264
(11)
12
BUT 9
15 w
♂
Wheat, soya bean meal 0
10.5 solid
0
7.5–10
(a): Technical dossier/Section IV/Annex 02.01/Supplementary information June 2013 and Supplementary information June
2016a/Annex 6.
(b): Technical dossier/Section IV/Annex 02.02 and supplementary information June 2013/Annex Q21-1.
(c): Technical dossier/Section IV/Annex 02.03/Supplementary information June 2013 and Supplementary information June 2016b/
Annex 2.
(d): Technical dossier/Section IV/Annex 02.04 and supplementary information June 2013/Annex Q23-1.
55 Technical dossier/Section IV/Annex 02.05 and supplementary information June 2013.
56 Technical dossier/Supplementary information June 2013/Annex Q24-4.
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Xylanase resulted in a signiﬁcantly higher ﬁnal body weight in trials 3 and 4 and in a better feed to
gain ratio in trial 4. Positive and signiﬁcant effects of the additive were seen in only two trials in turkeys;
therefore, the Panel is not in a position to conclude on the efﬁcacy of Belfeed B in turkeys for fattening.
3.3.3. Efﬁcacy for laying hens
Three long-term trials were submitted. The details of the study design are provided in Table 4 and
the results in Table 5. In the three studies the hens were fed either a non-supplemented diet (control) or
a diet containing Belfeed B xylanase at the intended dose of 10–10.5 IU/kg feed (conﬁrmed by analysis).
In the three trials xylanase was added in liquid and solid forms. In trial 2, two breeds (Lohmann brown,
LB; Lohmann selected light, LSL) of hens were used. Hens were under study for at least 24 weeks, and
feed intake and laying performance were measured on weekly intervals in trial 1 or on 4-week intervals
in trials 2 and 3. Feed to egg mass ratio was calculated. Health and mortality were monitored
throughout the study. The results of laying rate, egg mass and feed to gain ratio were analysed with an
ANOVA, cage basis, and comparison of group means was performed with the Tukey test.
Xylanase resulted in a better feed to egg mass ratio in three trials (in trial 2 only in the LB strain
and solid form); positive effects were also seen when incorporated in liquid form in trial 1 on the laying
rate and in trials 1, 2 (only in the LSL strain) and 3 on the daily egg mass per hen. Therefore, the
Panel concludes that the additive is efﬁcacious in laying hens at the dose of 10 IU/kg feed.
Table 3: Effects of Belfeed B xylanase on the performance of turkeys for fattening
Trial Treatments Sex
Feed intake
(kg)(1)
Final body
weight (kg)
Feed to
gain ratio
Mortality and
culling (%)
1 0 Males 0.30 11.5 3.02 8.0
10.5 solid 0.29 11.5 2.92 8.6
10.5 liquid 0.29 11.6 2.84 8.0
2 0 Females 13.5 6.1 2.25 2.5
10.5 solid 13.4 6.2 2.19 1.6
10.5 liquid 13.6 6.3 2.20 1.7
0 Males 30.8 12.8 2.45 1.1
10.5 solid 30.8 12.9 2.41 6.8
10.5 liquid 30.7 13.0 2.39 5.6
3 0 Females 0.15 8.1b 2.56 1.9
10.5 solid 0.15 8.6a 2.40 1.9
4 0 Males 23.2 11.0b 2.13a 3.8
10.5 solid 23.2 11.2a 2.09b 6.8
a,b: Within a column and within a trial, values with a different superscript are signiﬁcantly different (p < 0.05).
(1): In trials 1 and 3, data show daily feed intake and in trials 2 and 4, overall feed intake.
Table 4: Trial design and dosages of the efﬁcacy trials performed in laying hens
Trial
Total no. animals
(cage/replicate)(d)
Replicates/treatment
Breed
(age at start)
Duration
Diet composition
Enzyme activity
(IU/kg)
Intended Analysed
1(a) 1,152
(16 cages)
6
ISA Brown
(26 weeks)
26 weeks
Wheat, corn, soya bean 0
10.5 solid
10.5 liquid
0
11.5
11.0
2(b) 216/216
(4 cages)
36 (18 LB/18 LSL)
LB/LSL
(44 weeks)
24 weeks
Wheat, rye, soya bean 0
10.5 solid
10.5 liquid
0
12.3
10.8
3(c) 432
(6 cages)
8
Brown
(22 weeks)
24 weeks
Wheat, rye, soya bean 0
10 liquid
10 solid
0
9.9
8.0
(a): Technical dossier/Section IV/Annex 04.01 and Supplementary information June 2013/Annex Q25-1 and Q27-2.
(b): Technical dossier/Section IV/Annex 04.02 and Supplementary information June 2013/Annex Q25-1 and Q27-2.
(c): Technical dossier/Section IV/Annex 04.03 and Supplementary information June 2013/Annex Q25-1 and Q27-2.
(d): Four hens per cage in trial 1, one hen per cage in trial 2 and three hens per cage in trial 3.
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3.3.4. Efﬁcacy for ducks and other minor poultry species
The applicant submitted two efﬁcacy studies in ducks which had been previously evaluated by the
FEEDAP Panel (EFSA, 2006).57 The Panel considers that the mode of action of xylanase is well known
and is considered to be similar within avian species. Therefore, the conclusions on the efﬁcacy in
chickens for fattening and laying hens can be extrapolated to minor poultry species for fattening and
or laying/breeding when used at the same dose.
3.3.5. Efﬁcacy for weaned piglets
A total of 12 trials were submitted (including the tolerance trial). Eight of these studies were not
considered further in the assessment due to the short duration (from 36 to 41 days, shorter than the
required 42 days),58 the parameters measured (i.e. digestibility)59 or the unavailability of relevant
data/information.60
The details of the study design of the other four studies are provided in Table 6 and the results
in Table 7. The four studies were performed with weaned piglets and included groups with a
non-supplemented diet (control) or with a diet containing the Belfeed B xylanase at 10 IU/kg feed
(conﬁrmed by analysis). Trial 2 is the tolerance trial, described in the safety for the target species
section, had also a third group with Belfeed B xylanase (tolerance dose). The Panel notes that in three
of these trials (trials 2–4 below) the piglets received for at least 5 days medicated feed before the start
of the trial (medication included amoxicillin, colistin and zinc oxide).61 In the four trials, males and
females were used and in trial 1, the animals were distributed to the pens according to sex. Health
and mortality were monitored throughout the study, and body weight and feed intake were recorded.
Feed to gain ratio was calculated. The data were analysed with an ANOVA. No signiﬁcant differences
were observed in any of the trials with the supplementation of Belfeed B xylanase at the dose of
10 IU/kg feed compared to control.
The data from the four studies were pooled and analysed statistically; differences were considered
signiﬁcant at a level of at least p < 0.05.62 The groups studied included the control diet and the group
with 10 IU/kg feed. The parameters studied included feed intake, ﬁnal body weight, daily weight gain
and feed to gain ratio. Data were tested for normality and homogeneity. Daily feed intake and ﬁnal
body weight data were not homogeneous and were not further considered in the analysis. An ANOVA
was performed for the average daily weight gain and the feed to gain ratio, pen basis. The model
included the effect of trial, treatment and their interaction, and the initial body weight was used as a
Table 5: Effect of Belfeed B xylanase on the performance of laying hens
Trial Treatments Strain
Daily feed
intake (g)
Laying
rate (%)
Daily egg mass
per hen (g)
Feed to egg
mass
Mortality
(%)
1 0 116 93.1a 60.8b 1.91a 2.3
10.5 solid 114 93.2a 60.8b 1.88b 1.8
10.5 liquid 115 93.7b 61.4a 1.88b 3.1
2 0 LSL 121 94.0 63.8b 2.02 0
10.5 solid 118 93.0 64.6ab 1.99 0
10.5 liquid 120 92.8 64.8a 2.00 0
0 LB 128 93.0 68.4 2.02a 0
10.5 solid 124 92.8 69.0 1.96b 1.3
10.5 liquid 125 91.5 67.2 2.06a 0
3 0 115 94.2 56.6b 2.03a 2.6
10.5 solid 113 94.2 56.9b 1.99b 1.8
10.5 liquid 114 95.0 57.8a 1.97b 0.0
a,b: Within a column and within a trial, values with a different superscript are signiﬁcantly different (p < 0.05).
57 Technical dossier/Section IV/Annex 03.01 and 03.02.
58 Technical dossier/Section IV/Annexes 05.01, 05.02, 05.03, 05.06, 05.07 and 05.08.
59 Technical dossier/Section IV/Annex 05.04.
60 Technical dossier/Section IV/Annex 05.05.
61 Technical dossier/Supplementary information June 2016.
62 Technical dossier/Supplementary information January 2016.
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covariate. Results showed a signiﬁcant improvement in the feed to gain ratio in animals receiving
10 IU/kg compared to the control diet (1.36 vs 1.34) while no effect was observed on the average
daily weight gain.
Based on the results of the pooled data, which showed an improvement of the feed to gain ratio of
the piglets, the Panel concludes that the additive has some potential to be efﬁcacious in weaned
piglets at the dose of 10 IU/kg feed.
3.3.6. Efﬁcacy for pigs for fattening
Seven trials were assessed. The details of the studies are provided in Table 8 and the results in
Table 9. The studies were performed with pigs for fattening which were treated either with a
non-supplemented diet (control) or with a diet containing Belfeed B xylanase (solid or liquid) at an
intended dose of 10.5 IU/kg feed. The analysis of the feed showed that the intended dose was equal
or lower in most of the cases and therefore the dosage the animals received was not higher than the
dose that the applicant recommends (10 IU/kg feed). The duration of the study was at least
10 weeks. The animals raised in groups were sex separated in trials 1, 2, 6 and 7. All trials except
5 and 6 were done by raising the pigs to a certain body weight. Health and mortality were monitored
throughout the study, and body weight and feed intake were recorded. Feed to gain ratio was
calculated. An ANOVA was performed with the data. No signiﬁcant differences between the two dietary
groups were found in relevant parameters.
Table 6: Trial design and dosages of the efﬁcacy trials performed in weaned piglets
Trial
Total no. animals
(animals/replicate)
replicates/group
Breed
Sex
Age at start
Diet composition
Enzyme activity
(IU/kg)
Intended Analysed
1(a) 288
(12)
12
Pietrain 9 (Landrace 9 Large White)
♀,♂
28 days
Wheat, barley, soya
bean meal
0
10
0
10.3
2(b) 144
(6)
8
Pietrain 9 (Landrace 9 Large White)
♀,♂
28 days
Wheat, milk whey,
rye, barley, soya
bean meal
0
10
1,000
0
8
731
3(c) 72
(4)
9
Pietrain9 (Duroc 9 Landrace)
♀,♂
26 days
Wheat, milk whey,
rye, barley, soya
bean meal
0
10
0
11
4(a) 96
(4)
12
Pietrain 9 (Landrace 9 Large White)
♂,♀
26 days
Wheat, milk whey,
rye, barley, soya
bean meal
0
10
0
7.5
(a): Technical dossier/Supplementary information January 2016/Annex 3.03_2015.
(b): Technical dossier/Supplementary information January 2016/Annex 3.03_2012.
(c): Technical dossier/Supplementary information January 2016/Annex 3.03_2013.
Table 7: Effects of Belfeed B xylanase on the performance of weaned piglets
Trial
Enzyme
activity
(IU/kg)
Daily feed
intake (kg)
Body weight (kg) Daily body
weight
gain (kg)
Feed to
gain ratio
Dead and
culled (%)Initial Final
1 0 0.54 7.9 24.2 0.37 1.40 1.4
10 0.52 7.8 23.6 0.36 1.38 2.8
2 0 0.57 6.7 25.3 0.44 1.29a 8.3
10 0.57 6.7 25.5 0.45 1.28a 6.2
100 0.56 6.7 25.7 0.45 1.23b 4.1
3 0 0.79 9.0 33.8 0.58 1.37 5.5
10 0.77 9.0 33.2 0.56 1.37 8.3
4 0 0.56 7.1 24.4 0.41 1.36 8.3
10 0.54 7.1 24.1 0.41 1.34 2.1
a,b: Values within one column for the same study with different superscripts are different (p < 0.05).
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Table 8: Trial design and dosages of the efﬁcacy trials performed in pigs for fattening
Trial
Total no. animals
(animals/replicate)
Replicates/treatment
Breed
Sex
Diet
composition
Enzyme activity (IU/kg)
Intended Analysed
1(a) 80
(10)
4
Pietrain 9 Hybrid
♂castrated, ♀
Wheat, barley,
tapioca meal
0
10.5
0
7.9–9.9
2(b) 72
(6)
6
Pietrain 9 Hybrid
♂castrated, ♀
Wheat, barley,
peas
0
10.5
0
10.1–10.4
3(c) 80
(10)
4
Pietrain 9 Hybrid
♂castrated, ♀
Wheat, peas,
gluten feed
0
10.5
0
8.8–9.2
4(d) 46
(1)
23
Crossbred
♂castrated, ♀
Rye, barley, soya
bean meal
0
10.5
0
10.6–11.9
5(e) 56
(1)
28
Crossbred
♂castrated, ♀
Wheat, barley 0
10.5
0
8.0–8.2
6(f) 80
(5)
8
Crossbred
♂, ♀
Wheat, barley 0
10.5
0
9.3–8.5
7(g) 60
(5)
6
Crossbred
♂castrated, ♀
Wheat, barley,
peas
0
10.5
0
9.1–9.9
(a): Technical dossier/Section IV/Annex 06.01 and supplementary information June 2013.
(b): Technical dossier/Section IV/Annex 06.02 and supplementary information June 2013.
(c): Technical dossier/Section IV/Annex 06.03 and supplementary information June 2013.
(d): Technical dossier/Section IV/Annex 06.04 and supplementary information June 2013.
(e): Technical dossier/Section IV/Annex 06.05 and supplementary information June 2013.
(f): Technical dossier/Section IV/Annex 06.06 and supplementary information June 2013.
(g): Technical dossier/Section IV/Annex 06.07.
Table 9: Effects of Belfeed B xylanase on the performance of pigs for fattening
Trial
Enzyme activity
(IU/kg)
Daily feed
intake (kg)
Body weight (kg) Daily weight
gain (kg)
Feed to
gain ratio
Mortality and
culled (n)Initial Final
1 0 1.72 23 100 0.65 2.65 0
10.5 1.75 23 100 0.66 2.65 1
2 0 2.05 19 107 0.71 2.88 2
10.5 2.02 19 108 0.73 2.75 0
3 0 2.04 22 111 0.69 2.99 1
10.5 2.02 22 111 0.68 2.97 1
4 0 2.57 27 107 0.84 3.04 1
10.5 2.58 28 107 0.86 2.98 3
5 0 2.29 26 113 0.78 2.92 0
10.5 2.31 26 116 0.80 2.88 0
6 0♂ 2.28 43 108 0.95 2.39 2
10.5♂ 2.37 43 110 0.98 2.42 1
0♀ 2.22 43 99 0.82 2.70 1
10.5♀ 2.29 43 104 0.89 2.57 3
7 0 2.17b 29 112 0.83 2.62 4
10.5 2.28a 30 111 0.88 2.61 3
a,b: Values within one column for the same study with different superscripts are different (p < 0.05).
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The data from the seven studies were pooled and analysed statistically; differences were
considered signiﬁcant at a level of at least p < 0.05.63 The groups studied included the control diet
and the group with the intended dose of 10.5 IU/kg feed. The parameters studied included feed
intake, ﬁnal body weight, daily weight gain and feed to gain ratio. Data were tested for normality and
homogeneity. When a study had an impact on the homogeneity of the data it was removed from the
statistical analysis, so for ﬁnal body weight the seven trials were included; for average daily gain, trials
1, 2, 4, 5 and 6 were included and for feed to gain ratio, trials 3, 4, 5 and 6 were included. An
ANOVA was performed with the data considering two models (with or without the initial body weight
as a covariate) which took into account the effect of the treatment, the effect of the trial, sex and
their interactions. In all trials except trials 5 and 6, the animals remained under study up to a certain
body weight; therefore, the analysis of the ﬁnal body weight is of limited relevance for the efﬁcacy.
The results showed that the supplementation of the feed with Belfeed B xylanase improved
signiﬁcantly the average daily weight gain of the pigs (769 vs 791 g/day for control and Belfeed B
xylanase).
Based on the results of the pooled data, which showed an improvement of the average daily
weight gain of the pigs for fattening, the Panel concludes that the additive has some potential to be
efﬁcacious in pigs for fattening at the dose of 10 IU/kg feed.
3.3.6.1. Conclusions on efﬁcacy for the target species
Based on the results obtained in the efﬁcacy trials provided, the Panel concludes that the additive
has the potential to be efﬁcacious at the dose of 10 IU/kg feed in chickens for fattening, laying hens,
weaned piglets and pigs for fattening. The Panel considers that this conclusion can be extended to
chickens reared for laying and to breeding hens.
The Panel considers that the mode of action of xylanase is well known and is considered to be
similar within avian species. Therefore, the conclusions on the efﬁcacy in chickens for fattening and
laying hens can be extrapolated to minor poultry species for fattening and or laying/breeding when
used at the same dose.
Owing to the lack of sufﬁcient data, the Panel cannot conclude on the efﬁcacy of the product in
turkeys for fattening.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation64 and good
manufacturing practice.
4. Conclusions
Belfeed B does not give rise to safety concerns with regard to the genetic modiﬁcation of the
production strain. Neither the production strain nor its recombinant DNA was detected in the ﬁnal
product.
The additive is safe for chickens and turkeys for fattening, laying hens and weaned piglets at the
dose of 10 IU/kg feed. The Panel considers that the conclusions can be extended to chickens reared
for laying, turkeys reared for breeding, breeding hens and pigs for fattening. Also and based on the
wide margin of safety shown in major poultry species, the Panel considers that the conclusions can be
extrapolated to minor poultry species at the same dose.
The use of Belfeed B as a feed additive does not give rise to concerns for consumers.
The additive is not considered to be toxic by inhalation or irritant for skin or eye, but the
Panel cannot conclude on its skin sensitisation potential. Owing to the proteinaceous nature of the
active substance, the additive is considered a potential respiratory sensitiser.
The use of Belfeed B as a feed additive poses no risks to the environment.
The additive has the potential to be efﬁcacious at the dose of 10 IU/kg feed in chickens for
fattening, laying hens, weaned piglets and pigs for fattening. The Panel considers that this conclusion
can be extended to chickens reared for laying and to breeding hens and can also be extrapolated to
63 Technical dossier/Supplementary information January 2016/Annex 2.
64 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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minor poultry species for fattening and or laying/breeding. Owing to the lack of sufﬁcient data, the
Panel cannot conclude on the efﬁcacy of the product in turkeys for fattening.
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Methods of Analysis
for Belfeed B MP and Belfeed B ML
In the current application authorisation is sought under articles 4(1); 10(2) and 13(3) for Belfeed B
MP and Belfeed B ML under the category/functional 4(a) ‘zootechnical additives’/‘digestibility
enhancers’. Speciﬁcally, authorisation is sought for the use of the feed additive for chickens and
turkeys for fattening, chickens reared for laying, turkeys reared for breeding and for breeding
purposes, laying hens, other ducks, other minor poultry species for fattening and laying, weaned pigs
and pigs for fattening.
According to the Applicant, endo-1,4-b-xylanase (EC 3.2.1.8) is the active agent of Belfeed B MP &
ML produced by Bacillus subtilis - TD160(229) strain. The Applicant expresses the xylanase enzymatic
activity in international unit (IU), deﬁned as ‘the amount of enzyme which liberates one micromole of
reducing sugars (xylose equivalents) from beechwood xylan per minute at pH 4.5 and 30°C’.
The product is intended to be marketed as granulated and liquid formulations having a guaranteed
minimum xylanase activity of 400 IU/g. The carrier in the solid formulation is wheat ﬂour, while
glycerol and acetate buffer are used for the liquid formulation. The feed additive is intended to be
included through premixtures or directly in feedingstuffs to obtain a minimum activity of 10 IU/kg in
feedingstuffs for all the target species. For the quantiﬁcation of the xylanase activity in the feed
additive and premixtures the Applicant proposed the single laboratory validated ‘Skalar method’, a
method that according to the Applicant is only available in his laboratory. Upon request by the EURL
the Applicant submitted another single-laboratory validated and further veriﬁed colorimetric method for
the Quantiﬁcation of xylanase activity in the feed additive, based on the measurement of reducing
sugars (xylose equivalents) released by the action of xylanase on 3% beechwood xylan substrate in
the presence of 3.5-dinitrosalicylic acid (DNS) at pH 6.0 and 50°C (DNS method). The use of a
reference sample, consisting on a reference enzyme standard with a certiﬁed enzymatic activity
expressed in international units (IU), analysed in parallel with the feed additive samples when
determined using the DNS method, ensures the measurement traceability. Based on the performance
characteristics recalculated from the experimental data available the EURL recommends for ofﬁcial
control the proposed single-laboratory validated and further veriﬁed colorimetric method above
mentioned for the quantiﬁcation of the xylanase activity in the feed additive.
For the quantiﬁcation of the xylanase activity in feedingstuffs, the Applicant proposed a second
colorimetric method, based on the quantiﬁcation of water soluble dyed fragments produced by the
action xylanase on commercially available azurine cross-linked arabinoxylan substrates. The calibration
is conducted using a reference standard with a known enzyme activity expressed in IU. Upon request
of the EURL, the Applicant performed the analysis of premixture samples after a solid dilution with a
blank feed and applied the above mentioned method developed for feedingstuffs. Based on the
satisfactory performance characteristics recalculated from the experimental data available the EURL
recommends for ofﬁcial control the proposed single-laboratory validated and further veriﬁed
colorimetric method for the quantiﬁcation of the xylanase activity in premixtures and feedingstuffs.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
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